BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 10, 2008
 |  BioCentury  |  Product Development

Taking the pressure off

Given the cardiovascular safety concerns associated with non-steroidal anti-inflammatory drugs, NicOx S.A. believes the success of its naproxcinod - a nitric oxide-releasing version of naproxen - will stand or fall on the strength of its blood pressure differentiation. The company last week published data from the first study of the compound specifically designed to measure blood pressure versus naproxen, which is widely viewed as the NSAID with the most favorable cardiovascular profile.

In the Phase I 111 study, 118 patients suffering from both osteoarthritis and controlled hypertension received naproxcinod or naproxen at escalating doses over three weeks. The primary endpoint was the 24-hour ambulatory arterial blood pressure...

Read the full 517 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >